Mitsubishi Tanabe Pharma Corporation

Osaka University

Hiroaki Shitama

Kenji Morokuma

Norimitsu Hayashi

Osamu Sakurai

Ritsuo Imashiro

Hiroaki Sawamoto

Kunio Saruta

Hidekazu Tsujishima

Takashi Goi

Atsushi Sato

Nobuyuki Takakura

Yasuo Yamamoto

Maiko Hamada

Takashi Adachi

Shuhei Yamakoshi

Masahiko Miyashiro

Yuki Arai

Kazufumi Otsuki

Hiroko Wada

The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.

Lysophosphatidic acid derivative

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; Rrepresents an optionally substituted alkyl group or the like; Rrepresents a halogen atom or the like; and Ris an alkyl group substituted with an optionally substituted aryl group or the like, and Ris a hydrogen atom or the like; or Rand Rare terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof. 

Pyrrolidine compound and application as melanocortin receptor agonist

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

Growing community of inventors

Osaka, Japan

Hiroaki Shitama